Brief: Nicox Q2 Net Revenue At 0.6 Million Euros

Nicox SA

17/07/2020 06:38

July 17 (Reuters) - Nicox SA  NCOX.PA :
    * SECOND QUARTER 2020 BUSINESS UPDATE AND FINANCIAL
HIGHLIGHTS
    * Q2 2020 NET REVENUE OF EUR 0.6 MILLION AND CASH OF EUR
40.4
MILLION AS OF JUNE 30, 2020
    * RECENT DIVESTMENT OF VISUFARMA STAKE FURTHER STRENGTHENS
JULY
CASH POSITION BY EUR 5 MILLION
    * VYZULTA (®)PRESCRIPTIONS IN Q2 2020 INCREASED BY 36% OVER
Q2
2019
    * VYZULTA PRESCRIPTIONS IN Q2 2020 INCREASED BY 36% OVER Q2
2019
    * NCX 470 MONT BLANC PHASE 3 CLINICAL TRIAL INITIATED ON
SCHEDULE,
MORE THAN 40 SITES ACTIVATED TO ENROLL PATIENTS TO DATE
    * AS OF JUNE 30, 2020, NICOX GROUP HAD CASH AND CASH
EQUIVALENTS
OF EUR 40.4 MILLION
    * AS OF JUNE 30, 2020, NICOX GROUP HAD FINANCIAL DEBT OF EUR
17.7
MILLION IN FORM OF BOND FINANCING AGREEMENT WITH KREOS CAPITAL
SIGNED IN JANUARY 2019
    * WE DO NOT CURRENTLY ANTICIPATE DELAYS TO OUR CLINICAL
TIMELINE
DUE TO COVID-19 PANDEMIC
    * ZERVIATE U.S. PRESCRIPTIONS TOTALED 1,389 IN Q2 2020, THE
FIRST
FULL QUARTER OF SALES FOLLOWING LAUNCH IN THE U.S. IN MARCH 2020

Source text for Eikon:  ID:nGNE2wD3CD 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))